Journals / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 11

The value of posttreatment CA125 and PET/CT in predicting prognosis of epithelial ovarian cancer

Pages
1961–1966
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Aim: To investigate the association between post treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) and post treatment cancer antigen 125 (CA125) results and overall survival (OS) of patients with epithelial ovarian cancer (EOC).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To investigate the association between post treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) and post treatment cancer antigen 125 (CA125) results and overall survival (OS) of patients with epithelial ovarian cancer (EOC).
📊
Key Findings & Data:All cases and PET+ cases were evaluated separately.
💡
Conclusion & Impact:Our findings suggest that the post treatment CA125 value is more beneficial than PET results for the estimation of prognosis in EOC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: To investigate the association between post treatment F-18 fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) and post treatment cancer antigen 125 (CA125) results and overall survival (OS) of patients with epithelial ovarian cancer (EOC). Material and Methods: Survival was analyzed with Kaplan-Meier, Log-Rank and Cox proportional-hazards regression analyses. All cases and PET+ cases were evaluated separately. In addition, PET and CA125 results were evaluated together in the overall case group, and a survival analysis was made for the four defined groups. Results: The mean age of the 112 EOC-diagnosed patients was 54.9±0.9 years. Based on the PET/CT results, 48 patients were PETand 64 patients were PET+; and 59 patients were CA125- and 53 patients were CA125+. In the overall case group, OS was found to be significantly shorter in advanced stage patients when compared to the early stage patients, in the CA125+ patients when compared to the CA125- patients, and in the PET+ patients when compared to the PET- patients. A univariate analysis revealed a significant association between stage, CA125 and PET results, and OS. In a multivariate analysis, the association between stage and CA125 with OS was maintained, although the PET results were not significant. When the PET and CA125 results were evaluated together, the OS was significantly shorter in the CA125+/PET+ group than in the CA125-/PET-and CA125-/PET+ groups. In the PET+ group, CA125 and the time from diagnosis to positive PET result were identified as independent prognostic factors. Conclusion: Although OS had a tendency to be poorer in PET+ cases than negative cases, the PET results were not established as an independent prognostic factor for survival. Our findings suggest that the post treatment CA125 value is more beneficial than PET results for the estimation of prognosis in EOC.

🔖

Cite This Article

Budak, E., Ozeren, M., Tosun, G., Inan, A. H., Kanmaz, A. G., Beyan, E., Budak, A., Ileri, A., Aldemir, O. S. (2022). The value of posttreatment CA125 and PET/CT in predicting prognosis of epithelial ovarian cancer. Annals of Medical Research, Cilt: 28 - Sayı: 11, 1961–1966. https://ajindex.com/articles/445674

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424
  2. Palomar A, Nanni C, Castellucci P, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol 2012;14:123-9
  3. Morgan Jr RJ, Alvarez RD, Armstrong DK, et al. Epithelial ovarian cancer. J Natl Compr Canc Netw 2011;9:82-113
  4. Son H, Khan SM, Rahaman J, et al. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics 2011;31:569-83
  5. Huy NVQ, Van Khoa V, Tam LM, et al. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecol Oncol Rep 2018;25:110-4
  6. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining Progression of Ovarian Carcinoma During Follow-up According to Ca 125: A North Thames Ovary Group Study. Ann Oncol 1996;7:361-4
  7. Evangelista L, Palma MD, Gregianin M,et al. Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. J Turk Ger Gynecol Assoc 2015;16:137-44
  8. Jacobs I, Bast RC Jr. The CA125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12 9. Gallicchio R, Nardelli A, Venetucci A, et al. F-18 FDG PET/CT metabolic tumor volume predicts overall survival in patients with disseminated epithelial ovarian cancer. Eur J Radiol 2017;93:107-13
  9. Musto A, Grassetto G, Marzola MC, et al. Management of epithelial ovarian cancer from diagnosis to restaging: an overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET/ CT. Nucl Med Commun 2014;35:588-97
  10. Ledermann JA, Raja FA, Fotopoulou C, et al; ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:24-32
  11. Bast RC Jr, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody monitor the course of epithelial ovarian cancer. New Engl J Med 1983;309: 883-7
  12. Durmus Y, Meydanli MM. Risk of Malignancy Index Has a Poor Sensitivity in Detecting Borderline Epithelial Tumors and Non-Epithelial Ovarian Tumors. Gynecol Obstet Reprod Med 2019;25:101-6
  13. Barut F, Barut A, Kertis G, et al. Distri